VIRX OTC
Viracta Therapeutics, Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
1Y: -95.9%
3Y: -99.4%
5Y: -99.8%
$0.01
Last traded 2025-12-30 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
10 relationships8
As Filer
counterparties named
2
As Counterparty
mentioned by others
2
Rel. Types
2021-03-23
Earliest Filing
2024-05-30
Latest Filing
partner: 7
customer: 1
Counterparties (Filed by VIRX)
8 relationshipsCompanies named in VIRX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Day One Biopharmaceuticals, Inc. | DAWN | partner | License agreement partner for RAF monetization milestone | 2024-03-07 | View |
| DOT Therapeutcs-1, Inc. | — | partner | Successor in interest to Day One Biopharmaceuticals, Inc. | 2024-03-07 | View |
| XOMA (US) LLC | — | partner | Royalty Purchase Agreement counterparty | 2024-03-07 | View |
| Shenzhen Salubris Pharmaceutical Co. Ltd. | — | partner | Mutual termination of exclusive collaboration and license agreement for nanatinostat development. | 2021-08-23 | View |
| Jefferies LLC | JEF | partner | Sales agent for the Open Market Sale Agreement | 2021-05-28 | View |
| XOMA (US) LLC | — | customer | Paid $13.5 million for rights to future milestones and royalties from Viracta's license agreements | 2021-03-23 | View |
| DOT Therapeutics-1, Inc. | — | partner | Original licensor whose agreement rights were purchased by XOMA | 2021-03-23 | View |
| Denovo Biopharma LLC | — | partner | Original licensor whose agreement rights were purchased by XOMA | 2021-03-23 | View |
Mentioned As Counterparty
2 mentionsOther companies that named VIRX in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| DAWN Day One Biopharmaceuticals, Inc. | partner | Received $8.1 million from the PRV sale proceeds pursuant to a License Agreement. | 2024-05-30 | View |
| XOMAP XOMA Corp | partner | XOMA acquired rights to milestones and royalties for two drug candidates in exchange for an upfront payment. | 2021-03-24 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2025-02-05 | Costs Associated with Exit or Disposal Activities; Departure/Election of Directors; Appointment of O | View | |
| 2025-01-31 | Notice of Delisting or Transfer | View | |
| 2025-01-24 | Entry into Material Definitive Agreement; Triggering Events That Accelerate Obligation; Financial St | Agreement | View |
| 2025-01-17 | Notice of Delisting or Transfer | View | |
| 2024-12-26 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-11-29 | Notice of Delisting or Transfer | View | |
| 2024-11-22 | Notice of Delisting or Transfer | View | |
| 2024-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-06 | Costs Associated with Exit or Disposal Activities; Departure/Election of Directors; Appointment of O | View | |
| 2024-08-14 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-07-29 | Costs Associated with Exit or Disposal Activities | View | |
| 2024-06-20 | Submission of Matters to a Vote of Security Holders | View | |
| 2024-05-31 | Notice of Delisting or Transfer | View | |
| 2024-05-14 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2024-05-09 | Results of Operations and Financial Condition | View | |
| 2024-04-09 | Other Events | View | |
| 2024-03-20 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-03-07 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Financial S | Agreement | View |
| 2023-11-17 | Notice of Delisting or Transfer | View | |
| 2023-11-09 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR